

# Testing for Hereditary Breast and Gynecologic Cancer



## Hereditary Cancer Risk Assessment and/or Testing Are Recommended By:

**American College of Obstetrics & Gynecology (ACOG)<sup>1</sup>**

**US Preventive Services Task Force (USPSTF)<sup>2</sup>**

**American College of Medical Genetics and Genomics (ACMG) & National Society of Genetic Counselors (NSGC)<sup>3</sup>**

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)<sup>4-5</sup>**

## GUIDELINES RECOMMEND GENETIC TESTING IF YOUR PATIENTS HAVE PERSONAL OR FAMILY HISTORIES OF ANY OF THE FOLLOWING SIGNS\* OF HEREDITARY CANCER:



### **MULTIPLE CANCERS**

- > 2 or more primary cancers in the same person
- > 3 or more cancers on the same side of the family



### **RARE CANCERS**

- > Triple negative breast
- > Male breast
- > Ovarian
- > Pancreatic
- > Metastatic prostate



### **EARLY-ONSET CANCERS**

- > Breast cancer diagnosed at or before age 50
- > Uterine cancer diagnosed before age 50



### **ANCESTRY**

- > Ashkenazi Jewish with breast cancer

# HEREDITARY CANCER TESTING OPTIONS\*

5-14  
DAY  
TAT

## CancerNext®

Test addressing the most common hereditary cancers; National consensus management guidelines provide recommendations regarding risk management for **all genes** in the panel<sup>4-5</sup>

4-7  
DAY  
TAT

## BRCaPlus®

STAT test addressing hereditary breast cancer risk; National consensus management guidelines provide recommendations regarding risk management for **all genes** in the panel<sup>4</sup>

5-14  
DAY  
TAT

## BRCANext®

Test addressing hereditary breast and gynecologic cancers; National consensus management guidelines provide recommendations regarding risk management for **all genes** on the base panel<sup>4</sup>

Option to add on select limited evidence genes\*\*



Scan for more information on gene content.

\*Additional testing options available

\*\*Genes are considered "limited evidence" if association with cancer has been suggested but not confirmed due to limited evidence. Management guidelines are not available regarding risk management.

## Add +RNAinsight® to Find More Answers

+RNAinsight is Ambry's unmatched concurrent DNA/RNA hereditary cancer testing that delivers greater clarity and confidence in results and finds more positive patients who may otherwise be missed with DNA-only or reflexive RNA approaches.<sup>6-11</sup>



Identifies more positive patients who would otherwise be missed<sup>9,11</sup>



Reduces ambiguity by reducing the relative VUS rate<sup>7,9</sup>



No impact on turnaround time<sup>11</sup>



Provides functional data to address known data gaps in non-white patients<sup>9</sup>



## READY TO ADD GERMLINE TO YOUR TESTING WORKFLOW?

Contact your Ambry Representative, or scan here and we'll have your rep contact you.

### References

1. ACOG COMMITTEE OPINION, Number 793. Obstet Gynecol. 2019
2. US Preventive Services Task Force. (2019). BRCA-related cancer: risk assessment, genetic counseling and genetic testing
3. Hampel H, ACMG, NSGC, et al., Genetics in Medicine. 2014
4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. V2.2026. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 1, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. V1.2025. ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed February 1, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
6. Landrith T et al. npj Precision Oncology. 2020.
7. Karam R et al. JAMA Network Open. 2019.
8. Horton C et al. NPJ genomic medicine. 2022.
9. Horton C et al. JAMA Oncology. 2023
10. Horton C et al. Expanding the reach of paired DNA and RNA sequencing: Results from 450,000 consecutive individuals from a hereditary cancer cohort; (Oral Presentation Session 84 - Strategies to Interpret Germline Variants in Cancer Predisposition Genes). Presented at the Annual Meeting of The American Society of Human Genetics, November 8, 2024, in Denver, CO.
11. Ambry Genetics, internal data on file.

1 Enterprise, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 [ambrygen.com](https://www.ambrygen.com)

©2026 Ambry Genetics Corporation. All rights reserved. Ambry Genetics® is a registered trademark of Ambry Genetics Corporation.

MKT-ONCO-BRO-20048-EN v9 02.18.26